Publication | Closed Access

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

VaccinationVaccine SafetyVaccine DevelopmentAntibody PersistenceVaccine TargetImmunologyVirologySingle-dose AdministrationMedicinePhase 3B